Indivior 股东会高票通过收购 Supernus 的发股议案，属预期内程序性投票

----- tm2627549d1_8k.htm -----
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 15, 2026
INDIVIOR PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its
charter)
Delaware
001-37835
41-2520873
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
10710 Midlothian Turnpike
,
Suite
125
North Chesterfield
,
VA
23235
(Address of principal executive offices)
(Zip Code)
(
804
)
379-1090
(Registrant’s telephone number, including
area code)
Not Applicable
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common Stock, $0.001 par value per share
INDV
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company
¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 5.07
Submission of Matters to a Vote of Security Holders.
On October 15, 2026, Indivior
Pharmaceuticals, Inc. (“Indivior”) held a special meeting of its stockholders (the “Indivior Special Meeting”).
At the close of business on September 4, 2026, the record date for the Indivior Special Meeting, there were 118,031,934 shares of Indivior
common stock (“Indivior Shares”) outstanding and entitled to vote at the Indivior Special Meeting, of which 91,206,182 Indivior
Shares were present in person or represented by proxy at the Indivior Special Meeting, representing 77.27% of Indivior Shares outstanding
and entitled to vote, which constituted a quorum to conduct business at the Indivior Special Meeting. At the Indivior Special Meeting,
Indivior’s stockholders approved the proposal described below and which is described in greater detail in Indivior’s definitive
joint proxy statement/prospectus filed with the Securities and Exchange Commission on September 11, 2026. Stockholder action on a second
proposal, to approve one or more adjournments of the Indivior Special Meeting to a later date or time, if necessary or appropriate, including
adjournments to permit the solicitation of additional votes or proxies in favor of the Indivior Share Issuance Proposal (as defined below)
if there are insufficient votes at the time of such adjournment to approve such proposal, was not required and no vote was taken on that
proposal.
The final voting results with respect to the proposal
considered and voted upon at the Indivior Special Meeting are set forth below.
Proposal
1: Indivior Share Issuance.
To approve the issuance of the Indivior Shares in connection with the Merger as contemplated by
the Merger Agreement, including for purposes of complying with the applicable provisions of Nasdaq Rule 5635 (the “Indivior Share
Issuance Proposal”).
For
Against
Abstain
Broker Non-Vote
85,455,705
5,563,744
186,733
N/A
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INDIVIOR PHARMACEUTICALS, INC.
Date:
October 15, 2026
By:
/s/ Ryan Preblick
Name:
Ryan Preblick
Title:
Chief Financial Officer